These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24454461)

  • 1. Expression of Immunohistochemical Markers before and after Neoadjuvant Chemotherapy in Breast Carcinoma, and Their Use as Predictors of Response.
    Lee HC; Ko H; Seol H; Noh DY; Han W; Kim TY; Im SA; Park IA
    J Breast Cancer; 2013 Dec; 16(4):395-403. PubMed ID: 24454461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
    Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
    J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators?
    Chatterjee S; Saha A; Arun I; Nayak SS; Sinha S; Agrawal S; Parihar M; Ahmed R
    Breast Cancer (Dove Med Press); 2015; 7():381-8. PubMed ID: 26677343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.
    Bhargava R; Beriwal S; Dabbs DJ; Ozbek U; Soran A; Johnson RR; Brufsky AM; Lembersky BC; Ahrendt GM
    Cancer; 2010 Mar; 116(6):1431-9. PubMed ID: 20131351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist.
    Gahlaut R; Bennett A; Fatayer H; Dall BJ; Sharma N; Velikova G; Perren T; Dodwell D; Lansdown M; Shaaban AM
    Eur J Cancer; 2016 Jun; 60():40-8. PubMed ID: 27062316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proliferation rate and breast cancer subtype, but not ALDH1 expression, predict pathological response to neoadjuvant chemotherapy in locally advanced breast cancer.
    Chatterjee D; Bal A; Das A; Singh G
    Virchows Arch; 2015 Sep; 467(3):303-10. PubMed ID: 26063415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers Changes after Neoadjuvant Chemotherapy in Breast Cancer: A Seven-Year Single Institution Experience.
    Coiro S; Gasparini E; Falco G; Santandrea G; Foroni M; Besutti G; Iotti V; Di Cicilia R; Foroni M; Mele S; Ferrari G; Bisagni G; Ragazzi M
    Diagnostics (Basel); 2021 Nov; 11(12):. PubMed ID: 34943486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 changes to positive after neoadjuvant chemotherapy in breast cancer: A case report and literature review.
    Wang L; Jiang Q; He MY; Shen P
    World J Clin Cases; 2022 Jan; 10(1):260-267. PubMed ID: 35071526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in Invasive Breast Carcinomas after Neoadjuvant Chemotherapy Can Influence Adjuvant Therapeutic Decisions.
    Jaime Dos Santos B; Balabram D; Mara Reis Gomes V; Costa Café de Castro C; Henrique Costa Diniz P; Araújo Buzelin M; Buzelin Nunes C
    Cancer Res Treat; 2024 Jan; 56(1):178-190. PubMed ID: 37536712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of associations between molecular subtypes and responses to neoadjuvant chemotherapy in primary breast cancer patients].
    Zhou YJ; Ying M; He YJ; Liu YQ; Fan ZQ; Fan T; Li JF; Wang TF; Xie YT; Lu AP; Ouyang T
    Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(22):1711-5. PubMed ID: 24124677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic alterations in breast cancer associated with neoadjuvant chemotherapy: A comparison with baseline rates of change.
    Hariri N; Roma AA; Hasteh F; Walavalkar V; Fadare O
    Ann Diagn Pathol; 2017 Dec; 31():14-19. PubMed ID: 29146052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy.
    Rossi L; Verrico M; Tomao S; Ricci F; Fontana A; Spinelli GP; Colonna M; Vici P; Tomao F
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):105-111. PubMed ID: 31754747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study.
    Tang L; Li Z; Jiang L; Shu X; Xu Y; Liu S
    Front Oncol; 2022; 12():999716. PubMed ID: 36605428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of neoadjuvant chemotherapy on expressions of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in breast cancer.
    Qin Q; Gao F; Jiang W; Tan Q; Mo Q; Wei C
    Chin Med J (Engl); 2014; 127(18):3272-7. PubMed ID: 25266526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Soliman H; Wagner S; Flake DD; Robson M; Schwartzberg L; Sharma P; Magliocco A; Kronenwett R; Lancaster JM; Lanchbury JS; Gutin A; Gradishar W
    Ann Surg Oncol; 2020 Mar; 27(3):765-771. PubMed ID: 31907749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.
    Ohzawa H; Sakatani T; Niki T; Yasuda Y; Hozumi Y
    Breast Cancer; 2014 Sep; 21(5):563-70. PubMed ID: 23108629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Predictive Importance of Body Mass Index on Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer.
    Emirzeoglu L; Arici S; Sahin AB; Ocak B; Ak N; Ay S; Mammadov E; Turna H; Bilici A
    Breast Care (Basel); 2023 Feb; 18(1):42-48. PubMed ID: 36876171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.